Everolimus May Be Effective For NET In Gastrointestinal Tract, Lungs.
The latest clinical trial with everolimus (Afinitor, Novartis), showed the medication is effective for NETs originating in the gastrointestinal tract and the lungs. The RADIANT-4 was conducted in 302 patients with NETs of gastrointestinal or lung origin. The results show significant improvement in PFS, with median of 11 months everolimus vs 3.9 months placebo (hazard ratio, 0.48; P < .00001). The overall survival data are not yet mature, but they show a positive trend suggesting that everolimus reduces the risk for death by 37%. Another secondary end point was overall response rate, which was 64% with everolimus vs 26% on placebo. The findings were presented at the European Cancer Congress 2015
להמשך קריאה
Active Surveillance for Very Low Risk PTC? Stay Tune
Researchers from Kuma Hospital, Mayo Clinic and Memorial Sloan Kettering Hospital suggest a stratification of PTC patients to identify those suitable for a wait and see approach.
להמשך קריאה
Marizev, Merck’s Once-A-Week Januvia, Approved In Japan.
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved MARIZEV® (omarigliptin) 25 mg and 12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes. Japan is the first country to have approved omarigliptin. Merck will submit an FDA application soon.
להמשך קריאה
FDA Approves Two Diabetes Treatments
The FDA approved Novo Nordisk’s diabetes treatment Tresiba (Insulin degludec), a long-acting insulin for which the agency had previously denied approval in 2013. It also approved Novo Nordisk Ryzodeg 70/30 (insulin degludec/insulin aspart injection).
להמשך קריאה
Artificial Pancreas May Benefit Patients With Type 1 Diabetes.
A study presented at the EASD Meeting and published in NEJM indicated an artificial pancreas system using smartphone to help monitoring blood sugar and insulin delivery worked better than using devices separately. In the study, 33 adults used the system day and night, and 25 children and teens used it overnight. The blood sugar stayed at lower, healthier levels than when patients tried to manually manage their condition. Researchers conclude that a closed-loop system at home over a period of 12 weeks during free daily living is feasible in adults, children, and adolescents with type 1 diabetes.
להמשך קריאה
Diabetes Medication May Reduce Deaths From Cardiovascular Disease
Another study presented at the EASD meeting and published in NEJM found Jardiance [empagliflozin], lowered heart disease deaths by 38 percent and deaths from any cause by 32 percent over three years. Nearly four-fifths of the participants were already taking standard medicines for blood sugar, blood pressure and cholesterol.
להמשך קריאה
Invokana and Invokamet (canagliflozin): Drug Safety Communication
FDA strengthened warning for diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and decreased bone mineral density
להמשך קריאה
